Key keywords: FDA commissioner, drug approval decisions, regulatory backlash, pharmaceutical safety, clinical trial standards, FDA accelerated approval pathway, post-market drug surveillance, public health protection, congressional oversight, pharmaceutical industry regulation Speaking at a congressional oversight hearing on Tuesday, U.S. Food and Drug Administration (FDA) Commissioner Dr. Robert Califf publicly defended the agency’s recent drug approval decisions, pushing back against weeks of mounting criticism from patient advocacy groups, bipartisan lawmakers, and public health experts who argue the regulator has prioritized speed over safety in its review processes. The backlash erupted earlier this year after several high-profile drug approvals drew scrutiny: a controversial Alzheimer’s disease treatment approved via the accelerated pathway was found to have minimal clinical benefit for most patients while carrying a 30% higher risk of life-threatening brain swelling, a new class of weight-loss drugs faced reports of severe gastrointestinal side effects that were not fully disclosed in initial trial data, and a rare cancer drug was pulled from the market 18 months after approval when post-market studies confirmed it did not extend patient survival as promised. During his testimony, Califf emphasized that every FDA approval decision is rooted in rigorous, independent analysis of all available clinical trial data, with clear thresholds for both efficacy and safety that have been refined over decades of regulatory practice. He noted that the accelerated approval pathway, which has come under the sharpest criticism, was designed to give patients with unmet medical needs earlier access to promising treatments for conditions where no standard of care exists, and that the agency has already implemented new rules to require pharmaceutical manufacturers to complete confirmatory post-market trials two years faster than the previous requirement. Califf also pushed back against claims that the FDA is unduly influenced by pharmaceutical industry lobbying, noting that 90% of the agency’s drug review staff are career scientists with no financial ties to drugmakers, and that all conflict of interest disclosures are published publicly for every review panel. Califf added that the FDA has requested a 15% increase in its annual operating budget for fiscal year 2025, which would be used to hire 300 additional clinical reviewers and expand its post-market surveillance system to catch adverse event reports 40% faster than current capabilities. He concluded his remarks by noting that the agency approves 94% of drugs on its first review cycle, a rate that has stayed consistent for the past decade, while the rate of post-market safety withdrawals has dropped by 22% over the same period, countering claims that review standards have slipped.